Sanofi’s Journey & Strategy for Continuous Processing for Small Molecules

27th September 2021 | 10:00am EST | Flavien Susanne, Head of Chemical Development and Engineering at Sanofi |BOOK FREE SEAT FOR THIS WEBINAR

In the past decade, there has been a growing interest in the application of continuous processing in the pharmaceutical industry with 100s millions of investments and several products delivered to the market using this technology.

Continuous processing demonstrates several value propositions for the Pharmaceutical industry. Amongst them, we can name, access to better chemistry, product quality enhancement, reduction of CoGs but mostly speed to market where phase 3 to launch is drastically accelerated.

Sanofi R&D is building capacities to perform future GMP clinical batches using this technology. The first investment was completed last year, and we are in the process of expansion. It is a really changing time for science at Sanofi.

Sanofi is investing in modular concepts with a high capability of production of API and the ability of infinite reconfiguration. We are not only a thinking machine; to enhance our ability to always produce the best quality drugs for our patients, we are also implementing a digital twin system, tracking and controlling the quality of our product at any moment of time.

We are ready to meet the challenges of tomorrow and produce the new APIs to help patients.

Presented by Flavien Susanne, Head of Chemical Development Engineering at Sanofi

Flavien Susanne is a chemical engineer from the University of Normandy. He started his career at Pfizer in 2003 as part of the process development team working on the development of the flow team. Since Flavien, worked for Novartis, GSK, and more recently Sanofi.

Throughout the 17 years working within some of the most innovative Pharma, Flavien developed strong expertise in disruptive technology and CMC, leading new technology groups for the implementation of Pharma 4.0, including process intensification, big data, and filling following the QbD approach through modeling implementation.

Since 2020, Flavien has joined Sanofi as Head of Chemical Development & Process engineering, leading the implementation of continuous processing and digitalization as part of Synthetics

We will not sell your information to a third party. See our Privacy Policy